Selecta Biosciences Partners with Sanofi to Develop Antigen-Specific Immunotherapies for Allergies
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 12 (Table of Contents)
Published: 11 Dec-2012
DOI: 10.3833/pdr.v2012.i12.1859 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
As part of a global discovery collaboration, Sanofi has gained access to Selecta Biosciences’ SVP™ (Synthetic Vaccine Particle) platform to develop a targeted, antigen-specific immunotherapy for a life-threatening food allergy; it also has an option to develop two additional immunotherapies each to a specific food or aeroallergen...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS